Addex says adieu to CEO Vincent Mutel, as board looks for action
This article was originally published in Scrip
In professional sports it is not an uncommon sight to see a new owner come in and decide they want their own management to run the franchise in a manner that suits their style. So no one should be that surprised when the same happens in the biotech industry. Dr Vincent Mutel's departure as CEO of Addex Pharmaceuticals comes just months after the arrival of activist shareholder Biotechnology Venture Fund, which now owns 30% of the company, and the election of Oleg Nodelman to the company's board.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.